New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent CMRX news | >>
October 20, 2014
09:09 EDTCMRXEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
October 19, 2014
16:44 EDTCMRXEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTCMRXCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTCMRXBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTCMRXSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 16, 2014
11:48 EDTCMRXChimerix highlights FDA Ebola authorization, adds potential product candidate
Subscribe for More Information
08:49 EDTCMRXChimerix price target raised to $45 from $27 at William Blair
William Blair raised its price target for Chimerix shares to $45 after the company held a research and development update event. The firm added to its model brincidofovir sales for the treatment of adenovirus and says the opportunity to develop a treatment for Ebola represents potentially substantial upside to its estimates and valuation. The firm reiterates an Outperform rating on Chimerix.
07:08 EDTCMRXChimerix price target raised to $39 from $33 at Cantor
Cantor raised its price target on Chimerix after the company's Brincidofovir drug cut the death rate of patients with Adenovirus in half. The firm thinks the company is on track to file for approval of the drug in early 2016, and it keeps a Buy rating on the shares.
October 15, 2014
10:49 EDTCMRXEbola linked names rise again amid broader market sell-off
Subscribe for More Information
09:00 EDTCMRXChimerix volatility up, 2nd Texas health-care worker tests positive for Ebola
Chimerix October call option implied volatility is at 147, November is at 107, February is at 95; compared to its 4-week average of 81 according to Track Data, suggesting large price movement as the biopharmaceutical company collaborates with international consortium researching Ebola.
October 14, 2014
11:19 EDTCMRXNIH says several potential Ebola treatments under development
Subscribe for More Information
10:12 EDTCMRXBioCryst, Chimerix move higher after mention in NIH director blog post
10:10 EDTCMRXNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTCMRXChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
October 13, 2014
10:23 EDTCMRXChimerix to webcast their R&D presentation
R&D presentation to be held on October 15 at 4:30 pm. Webcast Link
07:17 EDTCMRXChimerix volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTCMRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTCMRXCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTCMRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTCMRXTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | all recent CMRX news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use